Shares of Edgewise Therapeutics EWTX were up more than 18% on Monday after it announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a ...

Such safety issues have disappointed investors, which likely caused the stock price to decline in the past week. EWTX had reported positive top-line data from Part A of the CIRRUS-HCM study in 2024.

Based on the above results, EWTX started the part B portion of the mid-stage study on EDG-7500 in patients with obstructive HCM. Initial data from this study is expected in the first quarter of 2025.

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against ...

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

Edgewise Therapeutics Inc EWTX Stock XNAS Rating as of May 21, 2025 Download PDF Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends ...

Check out our EWTX stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Edgewise Therapeutics, Inc. (EWTX) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...